[Form 4] Arcus Biosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Arcus Biosciences insider sale by Chief Accounting Officer. Alexander Azoy, listed as Chief Accounting Officer, reported a sale of 1,579 shares of Arcus Biosciences (RCUS) on 09/05/2025. The filing shows these shares were originally purchased on 05/30/2025 through the company Employee Stock Purchase Plan and were sold under a Rule 10b5-1 trading plan adopted 06/06/2025. The weighted-average sale price reported is $11.8797, with individual sale prices ranging from $11.55 to $12.22. After the reported sale, the reporting person beneficially owned 30,194 shares directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.

Positive

• Transaction disclosed promptly on Form 4 with full procedural details
• Sale executed under Rule 10b5-1 plan, providing affirmative defense documentation
• Origin of shares disclosed (purchased via Employee Stock Purchase Plan on 05/30/2025)

Negative

• Insider disposed of 1,579 shares, which may be viewed negatively by some market participants despite being pre-planned
• Weighted-average sale price $11.8797 may reflect realized liquidity at mid-$11 to $12 range

Insights

Securities Analyst

TL;DR: Routine insider sale under a 10b5-1 plan; transaction appears procedural and disclosed promptly.

The Form 4 documents a small, pre-planned disposition of 1,579 shares by the Chief Accounting Officer executed under a Rule 10b5-1 plan. The filing provides clear execution details: original acquisition via ESPP on 05/30/2025, 10b5-1 plan adoption on 06/06/2025, and a weighted-average sale price of $11.8797 across transactions priced $11.55–$12.22. The reporting person retains 30,194 shares post-transaction. From a market-impact perspective, the sale size is modest relative to typical institutional volumes and the disclosure satisfies Section 16 reporting requirements.

Corporate Governance Expert

TL;DR: Governance practices followed: use of 10b5-1 plan and timely Form 4 filing reduce appearance concerns.

The filer adopted a written 10b5-1 trading plan and marked the transaction accordingly, indicating an affirmative defense against insider trading allegations. The Form 4 discloses the source of shares (ESPP) and provides weighted-average pricing with a commitment to supply breakouts on request. The signature by an attorney-in-fact is noted. This record reflects standard governance and disclosure procedures for insider transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Azoy Alexander

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/05/2025		S		1,579(1)(2)	D	$11.8797(3)	30,194	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of 1,579 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025.

3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.55 to $12.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What shares did Alexander Azoy sell according to the RCUS Form 4?

The filing shows 1,579 shares of Arcus Biosciences common stock were sold on 09/05/2025.

Was the sale by the RCUS reporting person part of a pre-arranged plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on 06/06/2025.

What was the sale price range and weighted average for the RCUS sale?

Individual sale prices ranged from $11.55 to $12.22, with a reported weighted-average price of $11.8797.

How many Arcus Biosciences shares does the reporting person own after the sale?

The reporting person beneficially owned 30,194 shares following the reported transaction.

Where did the sold shares originate?

The sold shares consisted of shares purchased on 05/30/2025 through the company's Employee Stock Purchase Plan (ESPP).